Genor Biopharma Holdings Limited (HK:6998)
:6998
Top Page
Genor Biopharma Holdings Limited
(6998)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$2.50
▼(-18.30% Downside)
Action:UpgradedDate:01/29/26
The score is held back primarily by ongoing losses and continued cash burn despite the 2024 revenue rebound and strong gross margin, with additional pressure from a clear technical downtrend and a relatively high P/E with no dividend support.
Positive Factors
2024 revenue rebound
A large revenue step-up in 2024 establishes a recurring commercial base rather than prior minimal sales, improving visibility for near-term scale. Durable impact: sustained sales can fund R&D and manufacturing investment and improve operating leverage over months.
Negative Factors
Persistent negative cash flow
Negative operating and free cash flow across periods indicates ongoing cash burn despite revenue growth, requiring external funding or liquidity draws. This structurally limits reinvestment optionality and raises dilution or funding risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
2024 revenue rebound
A large revenue step-up in 2024 establishes a recurring commercial base rather than prior minimal sales, improving visibility for near-term scale. Durable impact: sustained sales can fund R&D and manufacturing investment and improve operating leverage over months.
Read all positive factors
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.60B
Dividend YieldN/A
Average Volume (3M)909.38K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth1447.56%
EPS GrowthN/A
CountryHK
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.38
Shares Outstanding2,011,213,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.72
Price to Sales (P/S)4.05
P/FCF Ratio-6.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Company Description
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) bi...
How the Company Makes Money
Genor Biopharma Holdings Limited generates revenue primarily through the commercialization of its proprietary biologic drugs and therapeutic products. The company’s revenue model includes sales of its approved drugs, licensing agreements, and stra...
Genor Biopharma Holdings Limited Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
74
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 224.00M | 206.23M | 0.00 | 15.93M | 0.00 | 10.33M |
| Gross Profit | 223.01M | 204.89M | 0.00 | 14.95M | 0.00 | 7.74M |
| EBITDA | 10.07M | -5.15M | -551.01M | -675.89M | -840.19M | -2.98B |
| Net Income | 20.15M | -51.28M | -674.36M | -730.40M | -865.37M | -3.03B |
Balance Sheet | ||||||
| Total Assets | 1.32B | 1.29B | 1.45B | 2.12B | 2.86B | 3.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.06B | 1.17B | 1.59B | 2.20B | 2.93B |
| Total Debt | 745.00K | 911.00K | 7.16M | 28.59M | 57.41M | 31.06M |
| Total Liabilities | 226.09M | 138.05M | 256.18M | 309.87M | 369.73M | 336.32M |
| Stockholders Equity | 1.10B | 1.15B | 1.19B | 1.80B | 2.49B | 3.23B |
Cash Flow | ||||||
| Free Cash Flow | -32.86M | -123.55M | -426.15M | -590.56M | -695.13M | -885.01M |
| Operating Cash Flow | -32.37M | -121.98M | -425.12M | -577.61M | -623.74M | -786.72M |
| Investing Cash Flow | -295.42M | 8.01M | 5.99M | -12.94M | -54.26M | -98.24M |
| Financing Cash Flow | 540.50K | -1.56M | -6.82M | -57.39M | 17.57M | 3.74B |
Genor Biopharma Holdings Limited Technical Analysis
Positive
3.06
Price Trends
2.70
Positive
2.93
Negative
3.21
Negative
Market Momentum
-0.02
Negative
55.25
Neutral
61.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Positive. The current price of 3.06 is above the 20-day moving average (MA) of 2.66, above the 50-day MA of 2.70, and below the 200-day MA of 3.21, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 55.25 is Neutral, neither overbought nor oversold. The STOCH value of 61.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6998.
Genor Biopharma Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$5.60B | -5.30 | 2.04% | ― | 1447.56% | ― | |
47 Neutral | HK$1.67B | -7.14 | -12.64% | ― | -38.38% | -22.12% | |
44 Neutral | HK$1.01B | -18.55 | -15.19% | ― | ― | 22.65% | |
43 Neutral | HK$1.68B | -6.43 | 293.08% | ― | ― | 27.90% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:6998
Genor Biopharma Holdings Limited
2.79
0.85
43.81%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.42
216.46%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.76
53.15%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.13
2.18
111.79%
HK:6622
Zhaoke Ophthalmology Ltd.
3.04
1.65
118.71%
HK:6978
Immunotech Biopharm Ltd
2.72
-0.55
-16.82%
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Launches Flexible On-Market Share Buyback Plan
Jan 22, 2026
Edding Genor Group Holdings Limited has announced that its board intends to conduct on-market share repurchases from time to time under a general mandate granted by shareholders at the company’s 26 June 2025 annual general meeting. The repur...
Edding Genor Outlines Board and Committee Structure to Bolster Governance
Dec 29, 2025
Edding Genor Group Holdings Limited has announced the current composition of its board of directors, listing executive, non-executive and independent non-executive directors, including Ni Xin and Zhai Jing as executive directors. The company also ...
Edding Genor Completes Reverse Takeover Merger and Major Corporate Overhaul
Dec 29, 2025
Edding Genor Group Holdings Limited has completed a very substantial acquisition via a merger between its merger subsidiary and the target company, with the transaction structured as a reverse takeover and satisfied through the issue of approximat...
Genor Biopharma Wins Approval to Drop Biotech “-B” Marker After Revenue-Boosting Merger
Dec 22, 2025
Genor Biopharma announced that the Hong Kong Stock Exchange has conditionally approved the dis-application of specific biotech listing rules to the company, effective upon completion of its proposed merger, after confirming that the enlarged group...
Genor Biopharma Shareholders Approve Merger, Whitewash Waiver and Capital Increase
Dec 22, 2025
Genor Biopharma Holdings Limited announced that all resolutions proposed at its extraordinary general meeting on 22 December 2025 were duly passed by poll, including approval of a merger agreement dated 13 September 2024 with a target company and ...
Genor Biopharma’s Lerociclib Gains Inclusion in China’s National Reimbursement Drug List
Dec 8, 2025
Genor Biopharma Holdings Limited announced the inclusion of its drug Lerociclib (GB491) in China’s National Reimbursement Drug List, effective January 2026. This inclusion is expected to enhance patient access, reduce financial burdens, and ...
Genor Biopharma Announces EGM and Member Register Closure
Dec 4, 2025
Genor Biopharma Holdings Limited, a company incorporated in the Cayman Islands, announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 22, 2025. The closure will occur from...
Genor Biopharma Announces Strategic Merger and Corporate Restructuring
Dec 4, 2025
Genor Biopharma Holdings Limited has announced a series of significant corporate actions, including a proposed merger, a reverse takeover, and an increase in authorized share capital. These moves are part of a strategic effort to enhance the compa...
Genor Biopharma Announces EGM for Merger and Retention Plan Approval
Dec 4, 2025
Genor Biopharma Holdings Limited has announced an Extraordinary General Meeting to be held on December 22, 2025, to discuss and potentially approve a proposed merger and a retention plan. The merger involves a specific mandate to issue shares to t...
Genor Biopharma Announces Major Corporate Actions and Proposed Merger
Nov 27, 2025
Genor Biopharma Holdings Limited has announced a series of significant corporate actions, including a proposed merger and a reverse takeover, which involve the issuance of consideration shares and a new listing application. The company is also see...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.